Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30010976HIVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS30004943HIVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS30003950HIVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS30083981HIVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS30081923HIVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS30066182HIVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS20021731HPVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS20043266HPVENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS44016588HTLV-1ENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TVIS44031572HTLV-1ENSG00000085511.20protein_codingMAP3K4NoNo4216Q9Y6R4
TCGA Plot Options
Drug Information
GeneMAP3K4
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009468
UniProt IDQ9Y6R4
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830